TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shionogi & Co ( (JP:4507) ) just unveiled an update.
Shionogi & Co., Ltd. announced that ViiV Healthcare presented results from the VOLITION study at the IAS 2025, showing that 89% of HIV patients preferred switching from daily oral therapy to the long-acting injectable Cabenuva. This preference highlights the potential for improved adherence and treatment satisfaction, reinforcing Shionogi’s commitment to infectious disease solutions and its strategic positioning in the global health market.
The most recent analyst rating on (JP:4507) stock is a Hold with a Yen2750.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, focusing on infectious diseases. It is committed to addressing major infectious diseases such as HIV, tuberculosis, and malaria through research and development, and works in partnership with ViiV Healthcare to advance treatment and prevention strategies.
Average Trading Volume: 2,431,918
Technical Sentiment Signal: Buy
Current Market Cap: Yen2131.5B
For detailed information about 4507 stock, go to TipRanks’ Stock Analysis page.